Aspirin 325 mg | Aspirin
Aspirin 325 mg (NSAID*)
*nonsteroidal anti-inflammatory drug
Pain reliever/fever reducer
Keep out of the reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.
Provides temporary relief of
Reye's syndrome: Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. When using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of Reye's syndrome, a rare but serious illness.
Allergy alert: Aspirin may cause a severe allergic reaction which may include
Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding. The chance is higher if you:
Do not use if you are allergic to aspirin or any other pain reliever/fever reducer
Ask a doctor before use if
Ask a doctor or pharmacist before use if you are taking a prescription drug for
Stop use and ask a doctor if
If pregnant or breast-feeding, ask a health professional before use. It is especially important not to use aspirin during the last 3 months of pregnancy unless definitely directed to do so by a doctor because it may cause problems in the unborn child or complications during delivery.
corn starch, microcrystalline cellulose, povidone
Mfg. by: Ultratab Laboratories, Inc., Highland, NY 12528
Dist. By: Hospak® Unit Dose Products, Rockford, IL 61114
Aspirin 325 mg
10 Coated Tablets
Drugs and Medications
DZA Brands, LLC Aspirin Drug Facts
SuperValu Inc. Aspirin Drug Facts
SuperValu Inc. Chewable Aspirin 81 mg Drug Facts
McKesson Aspirin Drug Facts
To determine the bioequivalence of new formula of aspirin relative to the established commercial effervescent aspirin when taken orally by healthy adult subjects
To determine the bioequivalence of new formula of aspirin relative to the established commercial aspirin plain tablet and aspirin dry granules when taken orally by healthy adult subjects
Aspirin resistance is the persistent platelet activation, demonstrated by platelet function tests (1). The hypothesis is that:LDL lowering by statin in patients with aspirin resistance ca...
The objective of this pilot study is to evaluate the prevalence of biological aspirin resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness will be m...
The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease. We hypothesize that certa...
Aspirin is a widely used medication for primary and secondary prevention of cardiovascular and cerebrovascular events. The gastrointestinal risks of aspirin are well known, but the frequency of gastro...
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in North America. Aspirin therapy has proven clinical effectiveness in the prevention and treatment of CVD and is one of th...
Aspirin-induced enteropathy is now increasingly being recognized although the pathogenesis of small intestinal damage induced by aspirin is not well understood and related risk factors have not been e...
Aspirin use has been associated with reduced mortality from cancer including prostate cancer in some studies. A number of anti-cancer mechanisms of aspirin have been proposed, including the inhibition...
Objective: The use of low-dose aspirin for primary prevention of cardiovascular events in patients at elevated risk for cardiovascular disease (CVD) is increasingly being questioned. Aspirin may not b...